AEON Biopharma, Inc., a biopharmaceutical company dedicated to advancing therapeutic alternatives in the neurotoxin space, has unveiled new analytical and functional data demonstrating that its ABP-450 product closely mirrors the structure and function of BOTOX® (onabotulinumtoxinA).
The data were presented at the 68th Annual Scientific Meeting of the American Headache Society, held from June 4-7, 2026, in Orlando, Florida. The presentation was delivered by Chad K. Oh, M.D., AEON’s Chief Medical Officer.
Understanding ABP-450 And Its Significance
ABP-450 is being developed as a biosimilar to BOTOX®, targeting therapeutic indications including chronic migraine. BOTOX® remains the only FDA-approved neurotoxin for chronic migraine, a condition affecting millions of patients in the U.S.
By establishing ABP-450’s comparability, AEON aims to provide an alternative treatment while expanding patient access. Biosimilars are designed to match existing biologics in structure, function, and efficacy, offering comparable therapeutic benefits under regulated manufacturing standards.
Analytical And Functional Comparisons
The presentation highlighted rigorous scientific analyses to assess ABP-450’s similarity to BOTOX®. Key methodologies included:
- Genomic Sequence Alignment: This assessment confirmed that ABP-450 shares a nearly identical genomic profile with BOTOX®, ensuring the core neurotoxin sequence is conserved.
- LC-MS Peptide Mapping: This technique examined the protein structure in detail, revealing 93-99% coverage of the neurotoxin component (BoNT/A1) and associated proteins (NTNH, HA70, HA33, HA17), with no variant peptides detected between the two products.
- LD50 Potency Assay: Functional testing showed that all ABP-450 lots fell within equivalence criteria defined by BOTOX® reference data, verifying that ABP-450 exhibits comparable biological activity.
These findings reinforce the conclusion that ABP-450 closely replicates BOTOX® both structurally and functionally.
Implications For Chronic Migraine Treatment
Chronic migraine is one of the primary therapeutic indications for botulinum toxins. Patients often struggle with frequent headaches, significant disability, and limited treatment options. By providing a biosimilar alternative, ABP-450 could increase patient access to effective therapy while maintaining the same safety and efficacy profile as BOTOX®.
The presentation at AHS serves as a critical step in advancing ABP-450 through the regulatory pathway for full therapeutic labeling in the United States. Data demonstrating high comparability help streamline potential FDA approval processes, aligning with the company’s goal of expanding treatment options for patients.
AEON Biopharma’s Role And Manufacturing Standards
AEON Biopharma has exclusive rights to develop and distribute ABP-450 for therapeutic purposes in the U.S., Canada, the European Union, the United Kingdom, and select international markets.
The product is manufactured by Daewoong Pharmaceutical in facilities authorized by the FDA, Health Canada, and the European Medicines Agency. These facilities ensure rigorous adherence to sterility, potency, and purity standards for all batches of ABP-450.
By leveraging existing manufacturing expertise and regulatory-compliant processes, AEON ensures that ABP-450 meets the high standards required for patient safety and therapeutic efficacy.
The American Headache Society Platform
The AHS Annual Scientific Meeting is a leading venue for headache specialists and researchers to share advances in clinical science, particularly in the management of chronic migraine. Presentations like ABP-450’s provide critical insight into emerging therapies, highlighting the importance of rigorous analytical evaluation for biosimilars.
Looking Ahead
ABP-450 represents a promising addition to the therapeutic neurotoxin market, which exceeds $3 billion annually in the United States.
By validating its structural and functional similarity to BOTOX®, AEON Biopharma strengthens the foundation for future clinical adoption and regulatory approval.
The company plans to continue generating clinical and analytical data to support ABP-450’s safety, efficacy, and regulatory pathway. These efforts aim to expand patient access to high-quality treatment for chronic migraine and other potential therapeutic indications.
About AEON Biopharma
AEON Biopharma is a U.S.-based biopharmaceutical company committed to developing biosimilar therapeutics. ABP-450 is a botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the brand name Jeuveau®.
AEON’s mission is to bring safe and effective therapeutic alternatives to patients while maintaining rigorous regulatory and manufacturing standards.
